Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.